JACK SU to Antineoplastic Agents
This is a "connection" page, showing publications JACK SU has written about Antineoplastic Agents.
Connection Strength
0.221
-
Maximizing the potential of aggressive mouse tumor models in preclinical drug testing. Sci Rep. 2021 06 02; 11(1):11580.
Score: 0.089
-
A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol. 2015 Feb; 17(2):303-11.
Score: 0.056
-
A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study. Pediatr Blood Cancer. 2013 Apr; 60(4):627-32.
Score: 0.049
-
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
Score: 0.028